CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens

CASI Pharmaceuticals

14/11/2025 21:17

Overview

CASI Q3 revenue falls 60% yr/yr due to estimated goods returns for EVOMELA

Net loss for Q3 2025 increased to $10.9 mln from $8.4 mln last year

Company appeals Nasdaq delisting determination, seeking extension to regain compliance

Outlook

CASI plans to complete China business divestiture by Q2 2026

Company to present CID-103 study results at ASH 2025 on Dec 7

CASI advancing CID-103 trials in U.S. and China

Result Drivers

REVENUE DECLINE - Revenue fell 60% yr/yr due to estimated goods returns for EVOMELA, which also impacted net loss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$3.08 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for CASI Pharmaceuticals Inc is $4.00, about 66.6% above its November 13 closing price of $1.34

Press Release: ID:nACS3mg51a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)